Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering, developing, and delivering potentially curative therapies that address the underlying drivers of heart disease. The company's mission is to transform the treatment paradigm for heart disease, which remains a leading cause of mortality globally, by focusing on the root molecular causes rather than merely managing symptoms. Headquartered in South San Francisco, California, Tenaya Therapeutics operates from its principal executive offices at 171 Oyster Point Blvd.

Tenaya Therapeutics develops therapies for both rare genetic disorders and more prevalent heart conditions, leveraging three distinct yet interrelated platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. Its pipeline includes several clinical-stage programs, such as TN-201, a gene therapy for MYBPC3-associated Hypertrophic Cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC); and TN-301, a small molecule HDAC6 inhibitor for Heart Failure with Preserved Ejection Fraction (HFpEF) and related cardio/muscular diseases. The company also maintains multiple early-stage preclinical programs aimed at addressing various forms of heart disease.

Recent notable developments for Tenaya Therapeutics, led by CEO Faraz Ali, M.B.A., include the announcement of interim data from its MyPEAK™-1 Phase 1b/2 trial for TN-201 in June 2026, which showed consistent signs of cardiac remodeling and symptom reduction in patients with MYBPC3-associated HCM. In May 2026, the company presented new clinical data from its RIDGE™-1 Phase 1b/2 trial of TN-401 for PKP2-associated ARVC. Additionally, in March 2026, Tenaya Therapeutics entered a research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics. The company's stock is traded on the NASDAQ Global Select Market under the ticker symbol TNYA.